Form 4: Arcellx CMO Sells Shares Under 10b5-1 Plan

Arcellx Chief Medical Officer Christopher Heery sold 12,396 shares of common stock for approximately $80.12 per share pursuant to a pre-arranged trading plan.

Summary

• Christopher Heery, Chief Medical Officer of Arcellx, Inc. (ACLX), reported a sale of common stock.
• The transaction involved the disposition of 12,396 shares of Arcellx common stock.
• The shares were sold at a weighted average price of $80.119 per share, with prices ranging from $80.00 to $80.41.
• The sale was executed on September 26, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which Mr. Heery entered into on March 23, 2025.
• Following this transaction, Mr. Heery beneficially owns 21,731 shares of Arcellx common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While it's an insider sale, the existence of a 10b5-1 plan mitigates the negative interpretation, suggesting a pre-scheduled liquidity event rather than a reaction to adverse company news.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than an immediate reaction to new information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence in the company's future prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the sale of shares by a Chief Medical Officer as a potential signal, though the pre-planned nature under a 10b5-1 plan often reduces concerns about immediate company prospects.

Key Dates

Recommendation

The sale by the Chief Medical Officer is a pre-planned transaction under a Rule 10b5-1 plan, which typically indicates a routine liquidity event rather than a change in the company's fundamental outlook. While insider selling can sometimes be a negative signal, the pre-arranged nature suggests it's not based on new, undisclosed information. Therefore, this single transaction alone does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Arcellx, ACLX, Insider Trading, Form 4, Stock Sale, Christopher Heery, Chief Medical Officer, 10b5-1 Plan